

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

ETS1-human

RRID:AB_2100688

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-350, RRID:AB_2100688

Antibody Information

URL: http://antibodyregistry.org/AB_2100688

Proper Citation: Santa Cruz Biotechnology Cat# sc-350, RRID:AB_2100688

Target Antigen: ETS1

Host Organism: rabbit

Clonality: polyclonal

Comments: Discontinued: 2016; ENCODE PROJECT External validation DATA SET is released testing lot A1608 for GM12878, induced pluripotent stem cell; status is eligible for new data (via exemption)

Antibody Name: ETS1-human

Description: This polyclonal targets ETS1

Target Organism: homo sapiens

Antibody ID: AB_2100688

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-350

Record Creation Time: 20250819T233454+0000

Record Last Update: 20250820T054703+0000

Ratings and Alerts

- ENCODE PROJECT External validation for lot: A1608 is available under ENCODE ID: ENCAB000AGG - ENCODE

<https://www.encodeproject.org/antibodies/ENCAB000AGG>

Warning: Discontinued: 2016

Discontinued: 2016; ENCODE PROJECT External validation DATA SET is released testing lot A1608 for GM12878, induced pluripotent stem cell; status is eligible for new data (via exemption)

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chandra A, et al. (2023) Quantitative control of Ets1 dosage by a multi-enhancer hub promotes Th1 cell differentiation and protects from allergic inflammation. *Immunity*, 56(7), 1451.

Murai Y, et al. (2021) Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway. *iScience*, 24(10), 103173.

Pham D, et al. (2019) Batf pioneers the reorganization of chromatin in developing effector T cells via Ets1-dependent recruitment of Ctcf. *Cell reports*, 29(5), 1203.

Belver L, et al. (2019) GATA3-controlled nucleosome eviction drives MYC enhancer activity in T-cell development and leukemia. *Cancer discovery*, 9(12), 1774.